Intranasal Delivery of Hypoxia Primed Whartons Jelly MSC Derived sEVs Reprograms Neuroimmune Signalling and Ameliorates Behavioural Deficits in a Valproic Acid Induced Mouse Model of Autism Spectrum Disorder

This study demonstrates that intranasal delivery of hypoxia-primed Wharton's jelly mesenchymal stem cell-derived small extracellular vesicles (WJ-H-sEVs) effectively ameliorates behavioral deficits and neuroinflammation in a valproic acid-induced mouse model of autism spectrum disorder by reprogramming neuroimmune signaling through the activation of the Nrf2 pathway and suppression of NF-κB and JAK-STAT signaling.

The Gist

Imagine Autism Spectrum Disorder (ASD) not just as a developmental hiccup, but as a complex storm inside the brain. This storm involves both the way the brain is built and a slow, progressive wear-and-tear (neurodegeneration) that current therapies often can't stop. The researchers in this paper wanted to find a better way to calm this storm.

They decided to look at "tiny messengers" called sEVs (small extracellular vesicles). Think of these as microscopic delivery trucks that cells send out to carry repair instructions and supplies to other cells. These trucks come from "Mother Cells" known as Mesenchymal Stem Cells (MSCs).

The Great Experiment: Choosing the Right Truck and the Right Driver
The scientists had two big questions:

1. Where should the trucks come from? They compared trucks made from cells taken from Bone Marrow (the deep inside of bones) versus Wharton's Jelly (a soft, gel-like tissue found in the umbilical cord).
2. How should the trucks be prepared? They tested two conditions:
   • Normoxic: The cells were grown in normal air (like a standard office).
   • Hypoxic: The cells were grown in low-oxygen conditions (like a high-altitude mountain). The researchers suspected that stressing the cells with low oxygen might make the trucks carry better, more powerful cargo.

The Results: The "Super-Charged" Umbilical Cord Trucks
The study found that the Wharton's Jelly trucks, when hypoxia-primed (stressed with low oxygen), were the clear winners. Let's call them the "Super-Trucks."

• Better Cargo: These Super-Trucks were packed with special "repair codes" (microRNAs) that are excellent for brain health.
• Better Delivery: When tested in a lab, these trucks were much better at getting into brain cells and immune cells (microglia) than the others.
• The Repair Job: Once inside, they helped brain cells grow, fixed damaged power plants (mitochondria), and acted like a fire extinguisher against inflammation and oxidative stress (rust/damage).

The Delivery Method: Sniffing the Medicine
Instead of injecting these trucks into the bloodstream, the researchers used a clever trick: intranasal delivery. They sprayed the Super-Trucks up the noses of mice with ASD-like symptoms.

• The Analogy: Think of the nose as a direct highway tunnel leading straight to the brain, bypassing the traffic jams of the rest of the body.
• The Outcome: Within 12 hours, the trucks arrived in the brain. The mice showed real improvements: they were less anxious, remembered things better, and learned spatial tasks more easily.

How It Works: The Internal Switches
The paper explains that these trucks didn't just magically fix things; they flipped specific switches inside the brain cells:

• They turned ON the "Antioxidant Shield" (the Nrf2 pathway), which protects the brain from damage.
• They turned OFF the "Inflammation Alarm" (the NF-κB and JAK-STAT pathways), which stops the brain from being in a constant state of panic and swelling.
• They lowered the "bad" inflammatory signals in the blood and increased the "good" calming signals.

The Bottom Line
This study suggests that using Wharton's Jelly cells, stressed with low oxygen, and delivering them via the nose is a highly effective way to repair brain damage and improve behavior in this mouse model of autism. The researchers conclude that this "hypoxia priming" is a smart strategy to make these cell-free therapies work better, offering a potential, kid-friendly way to help manage ASD symptoms by targeting the biology of the disorder directly.

Technical Summary

Technical Summary: Intranasal Delivery of Hypoxia-Primed Wharton's Jelly MSC-Derived sEVs in an ASD Mouse Model

Problem Statement
Autism Spectrum Disorder (ASD) is characterized not only by disrupted neurodevelopment but also by progressive neurodegenerative alterations that remain refractory to standard behavioral therapies. While Mesenchymal stem cell (MSC)-derived small extracellular vesicles (sEVs) have emerged as potent neuroprotective agents, critical gaps remain in defining the optimal MSC tissue source and the strategies required to enhance their efficacy for clinical translation. Specifically, while hypoxic preconditioning is known to potentiate therapeutic effects in MSCs, its specific impact on ASD-related impairments and the comparative efficacy of sEVs from different tissue sources (Bone Marrow vs. Wharton's Jelly) under varying oxygen conditions have not been established.

Methodology
This study employed a comprehensive in vitro and in vivo approach to evaluate the neuroregenerative efficacy of sEVs derived from human Bone Marrow (BM) and Wharton's Jelly (WJ) MSCs.

• Cell Culture Conditions: MSCs were cultured under normoxic (21% O₂) and hypoxic (1% O₂) conditions to generate four distinct sEV populations.
• In Vitro Assays: Neural stem cells (C17.2) and microglial cells (N9) were used to assess sEV uptake, cell proliferation, neurodifferentiation, mitochondrial health, and immunomodulatory effects.
• In Vivo Model: ASD-like phenotypes were induced in C57BL/6 mice via prenatal exposure to valproic acid (600 mg/kg).
• Delivery and Imaging: Fluorescently labeled hypoxia-primed WJ MSC-derived sEVs (WJ-H-sEVs) were administered intranasally. Biodistribution was tracked using IVIS imaging.
• Behavioral and Molecular Analysis: Post-treatment, mice underwent behavioral assessments for anxiety, recognition memory, and spatial learning. Post-mortem brain tissues were analyzed for neuroinflammation, oxidative stress, synaptic integrity, and signaling pathways (Nrf2, NF-κB, JAK-STAT) via immunofluorescence, Western blotting, and qRT-PCR. Systemic cytokine levels were quantified via ELISA. Mechanistic involvement was further validated using pharmacological inhibitors.

Key Results

• Optimization of sEVs: Comparative analysis demonstrated that hypoxic priming significantly enhanced sEV yield and enriched neuroprotective miRNAs. WJ-H-sEVs specifically exhibited elevated levels of miR-125b-5p, miR-21a-5p, and miR-145a-5p.
• Superior Efficacy of WJ-H-sEVs: In in vitro models, WJ-H-sEVs outperformed both normoxic counterparts and BM-derived sEVs. They demonstrated superior cellular uptake in neural stem cells and microglia, enhanced neurodifferentiation, robust antioxidant activity, effective immunomodulation, and improved mitochondrial health.
• In Vivo Biodistribution and Behavioral Improvement: Intranasally administered WJ-H-sEVs efficiently localized to the brain within 12 hours. Treatment significantly ameliorated ASD-like behaviors, including reductions in anxiety-like behavior and improvements in recognition memory and spatial learning.
• Molecular Mechanisms: The therapeutic benefits were associated with reduced neuroinflammation and oxidative damage, enhanced neuronal survival, decreased serum IL-6, and increased IL-10 and TGF-β. Mechanistically, these effects were mediated through the activation of the Nrf2 antioxidant pathway and the suppression of NF-κB and JAK-STAT signaling pathways.

Significance and Claims
The study establishes hypoxia as a clinically exploitable priming strategy to enhance the neuroregenerative performance of tissue-specific MSC-derived sEVs. It identifies Wharton's Jelly as a superior tissue source over Bone Marrow when combined with hypoxic preconditioning for ASD applications. Furthermore, the research demonstrates the translational feasibility of intranasal delivery, positioning WJ-H-sEVs as a potential adjunctive, cell-free, and pediatric-friendly neurotherapeutic modality for managing ASD. The findings suggest that this approach holds potential applicability across various MSC sources and other neurological disorders involving neuroinflammation and oxidative stress.